The adverse impact of IKZF1 deletion that was reported in Ph+ ALL patients treated with chemotherapy and TKI was also observed in the D-ALBA study with the use of blinatumomab and dasatinib (33). Here, IKZF1 is linked to acute lymphoblastic leukemia.